
Asia Pacific Insomnia Market Analysis
Asia Pacific Insomnia Market Research Report, By Types Of Therapy (Pharmacological Therapy And Non-Pharmacological Therapy), By Drug Formulation (Capsules, Tablet And Others), By Type Of Diseases (Poor Quality Of Sleep, Sleep Maintenance And Other) - Forecast Till 2035

Market Summary
As per Market Research Future Analysis, the Asia Pacific Insomnia Market was valued at USD 0.14 Billion in 2023 and is projected to grow to USD 0.20 Billion by 2032, with a CAGR of 8.12% from 2024 to 2032. Insomnia, the most prevalent sleep disorder, affects a significant portion of the population, particularly women and younger individuals. Factors such as increased alcohol, caffeine, and tobacco consumption, along with psychological and behavioral issues, are driving the rise in insomnia cases. The market is further supported by technological advancements and rising healthcare expenditures. However, a lack of education and awareness may hinder growth.
Key Market Trends & Highlights
The Asia Pacific Insomnia Market is witnessing significant growth driven by various factors.
- Market Size in 2023: USD 0.14 Billion
- Projected Market Size by 2032: USD 0.20 Billion
- CAGR from 2024 to 2032: 8.12%
- Japan holds the largest market share, with 1 in 5 people affected by insomnia.
Market Size & Forecast
2023 Market Size | USD 0.14 Billion |
2024 Market Size | USD 0.18 Billion |
2032 Market Size | USD 0.20 Billion |
CAGR | 8.12%. |
Major Players
Key players include Takeda Pharmaceutical Company, Pfizer, Inc., Eisai, Co., Merck & Co Inc, Sanofi, and GlaxoSmithKline Plc.
Market Trends
Asia Pacific Insomnia Market Market Drivers
Market Segment Insights
Regional Insights
Key Companies in the Asia Pacific Insomnia Market market include






Industry Developments
Market Segmentation
Asia Pacific Insomnia Market Segmentation
- Manufacturing and packaging industries
- Insomnia devices and drug manufacturers
- Insomnia devices and drug suppliers
- Biotechnology Companies
- Bio-Pharmaceutical Companies
- Research and Development (R&D) Companies
- Government Research Laboratories
- {" "=>[]}
Report Scope
Attribute/Metric | Details |
Market Size | USD 0.20 Billion by 2032 |
CAGR | 8.12% (2024-2032) |
Base Year | 2023 |
Forecast Period | 2024-2032 |
Historical Data | 2021 |
Forecast Units | Value (USD Billion) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | Types, end user, Region |
Geographies Covered | Asia Pacific |
Key Vendors | Takeda Pharmaceutical Company (Japan), Pfizer, Inc. (US), Eisai, Co. (Japan), Merck & Co Inc (US), Sanofi (France), GlaxoSmithKline Plc. (UK), Meda Consumer Healthcare Inc (US), Care Fusion Corporation (US), Pernix Therapeutics (US), Purdue Pharma L.P. (US), Consumer Healthcare Inc. (Canada), Dainippon Sumitomo (Japan), ECR Pharmaceuticals (US), Johnson & Johnson (US), Astellas (UK), Biocodex S A (France), Neurim (Switzerland), Flynn Pharma (UK) |
Market Highlights
Author
Latest Comments
This is a great article! Really helped me understand the topic better.
Thanks for sharing this. I’ve bookmarked it for later reference.
FAQs
-
Table of Contents 1 INTRODUCTION
- DEFINITION
-
SCOPE OF STUDY
- RESEARCH OBJECTIVE
- ASSUMPTIONS & LIMITATIONS
- MARKET STRUCTURE:
-
2 Research Methodology
- RESEARCH PROCESS:
- PRIMARY RESEARCH
- SECONDARY RESEARCH:
-
3 MARKET DYNAMICS
- DRIVERS
- RESTRAINTS
- OPPORTUNITIES
- MACROECONOMIC INDICATORS
-
4 MARKET FACTOR ANALYSIS
- PORTERS FIVE FORCES MODEL
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF BUYERS
- THREAT OF NEW ENTRANTS
- THREAT OF SUBSTITUTES
- INTENSITY OF RIVALRY
-
ASIA PACIFIC INSOMNIA MARKET, BY TYPES OF THERAPY
-
PHARMACOLOGICAL THERAPY
- BENZODIAZEPINES
- NON-BENZODIAZEPINES
- MELATONIN RECEPTOR AGONISTS
- OTHER
-
NON PHARMACOLOGICAL THERAPY
- RELAXATION THERAPY
- COGNITIVE BEHAVIORAL THERAPY
- SLEEP HYGIENE EDUCATION
- STIMULUS CONTRO
- PARADOXICAL INTENTION
- OTHER
-
PHARMACOLOGICAL THERAPY
-
ASIA PACIFIC INSOMNIA MARKET, BY DRUG FORMULATION
- CAPSULES
- TABLET
- OTHERS.
-
ASIA PACIFIC INSOMNIA MARKET, BY TYPE OF DISEASE
- POOR QUALITY OF SLEEP
- SLEEP MAINTENANCE
- OTHER.
-
GLOBAL INSOMNIA MARKET, BY REGION
-
INTRODUCTION
- JAPAN
- CHINA
- INDIA
- AUSTRALIA
- REPUBLIC OF KOREA
- REST OF ASIA-PACIFIC
-
INTRODUCTION
-
Competitive Landscape
-
MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
- STRATEGIC PARTNERSHIP
- MERGER & ACQUISITION
-
MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
-
10 COMPANY PROFILE
-
EISAI, CO.
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- KEY DEVELOPMENTS
-
MERCK & CO INC
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- KEY DEVELOPMENTS
-
TAKEDA PHARMACEUTICAL COMPANY
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- STRATEGY
- KEY DEVELOPMENT
-
SANOFI
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- KEY DEVELOPMENTS
-
PFIZER, INC.
- OVERVIEW
- PRODUCT OVERVIEW
- FINANCIALS
- KEY DEVELOPMENTS
- OTHERS
-
EISAI, CO.
-
CONCLUSION
-
12 Key Findings
-
FROM CEO’S VIEWPOINT
- UNMET NEEDS OF THE MARKET
- KEY COMPANIES TO WATCH
- PREDICTION OF INSOMNIA CARE INDUSTRY
-
FROM CEO’S VIEWPOINT
-
APPENDIX
-
Insomnia Market Segmentation
Market Segmentation Overview
- Detailed segmentation data will be available in the full report
- Comprehensive analysis by multiple parameters
- Regional and country-level breakdowns
- Market size forecasts by segment

Free Sample Request
Kindly complete the form below to receive a free sample of this Report
Customer Strories
“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”
Leave a Comment